Last updated: 11/07/2018 07:40:10
Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID
Trial description: The primary objective of this study is to evaluate the efficacy and safety of adding GSK2190915 300mg or placebo tablets administered once daily to fluticasone propionate/salmeterol 250/50mcg inhalation powder administered twice daily in uncontrolled asthmatic subjects > or = 18 years of age over the course of 6 weeks treatment. The secondary objectives are to undertake an exploratory analysis of the efficacy and safety of adding montelukast 10mg administered once daily to fluticasone propionate/salmeterol 250/50mcg inhalation powder administered twice daily and to investigate the pharmacokinetics and pharmacodynamics of GSK2190915 in uncontrolled asthmatic subjects > or = 18 years of age over the course of 6 weeks treatment.
Primary purpose:
Diagnostic
Trial design:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Trough (AM or morning pre-dose and pre-rescue bronchodilator) Forced Expiratory Volume in 1 second (FEV1) at the end of the 6 week treatment period
Timeframe: Week 6
Secondary outcomes:
Daily trough (AM pre-dose and pre-rescue bronchodilator) Peak expiratory flow (PEF) averaged over the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Daily PM or evening PEF averaged over the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Daily (average of AM and PM) PEF averaged over the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Daily asthma symptom score averaged over the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Daily rescue Short-Acting Beta2-Agonist (SABA) use averaged over the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Percentage of symptom-free days during the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Percentage of symptom-free nights during the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Percentage of rescue-free days during the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Percentage of rescue-free nights during the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Percentage of nights without awakenings due to asthma during the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Number of participants withdrawn due to lack of efficacy during the last 3 weeks of the 6 week treatment period
Timeframe: Week 4 to Week 6
Interventions:
Enrollment:
145
Primary completion date:
2011-11-10
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Snowise N, Clements D, Ho Shu-Yen , Follows R.Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.Curr Med Res Opin.2013;29(12):1663-1674
Medical condition
Asthma
Product
fiboflapon, fluticasone propionate, fluticasone propionate/salmeterol, salmeterol
Collaborators
Not applicable
Study date(s)
December 2010 to October 2011
Type
Interventional
Phase
2
Participation criteria
Sex
Female
Age
18+ years
Accepts healthy volunteers
No
- Age: 18 years of age or older
- Non-, former or current smokers with a documented smoking history of ≤ 10 pack years
- History of life-threatening asthma
- Recent asthma exacerbation
Inclusion and exclusion criteria
Inclusion criteria:
- Age: 18 years of age or older
- Non-, former or current smokers with a documented smoking history of ≤ 10 pack years
- Asthma diagnosis as defined by the National Institutes of Health
- Best FEV1 of 50% to <80% of the predicted normal value
- For current and former smokers, a post-albuterol FEV1/FVC ratio of >0.70 at Visit 1/1a (between 5:00AM and 12:00 noon)
- ≥ 12% and ≥200mL reversibility of FEV1
- Must have been using FP/SAL 250/50mcg inhalation powder BID for at least 2 weeks just prior to Visit 1.
- Must be able to replace their current short-acting beta2-agonists with albuterol inhalation aerosol
- Must be able and willing to give written informed consent to take part in the study.
- Must be able and willing to comply with all aspects of the study including completion of daily e-Diary.
Exclusion criteria:
- History of life-threatening asthma
- Recent asthma exacerbation
- Concurrent respiratory disease
- Recent respiratory infection
- Liver disease
- Other concurrent diseases/abnormalities
- Oral candidiasis
- Drug allergy
- Milk protein allergy
- Immunosuppressive Medications
- Administration of systemic, oral or depot corticosteroids within 12 weeks of Visit 1
- OATP1B1 substrates within 4 weeks of Visit 1
- Cytochrome P450 3A4 (CYP 3A4) Inhibitors
- Cytochrome P450 3A4 (CYP 3A4) Inducers
- Investigational Medications
- Compliance: any infirmity, disability, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol
- Affiliation with Investigator’s Site
Trial location(s)
Showing 1 - 6 of 15 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2011-11-10
Actual study completion date
2011-11-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website